Skip to main content

Table 1 Clinical characteristics

From: Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

  546 RP patients included on TMA
Age at RP (years), median (range) 63 (34–76)
Pathological GS
 < 7, n (%) 229 (41.9)
 ≥ 7, n (%) 317 (58.1)
Pathological T stage
 ≤pT2c, n (%) 363 (66.5)
 ≥pT3a, n (%) 182 (33.3)
 Unknown, n (%) 1 (0.2)
Preoperative PSA
 PSA ≤ 10 ng/ml, n (%) 222 (40.7)
 PSA > 10 ng/ml, n (%) 324 (59.3)
Surgical margin status
 Negative, n (%) 366 (67.0)
 Positive, n (%) 175 (32.1)
 Unknown, n (%) 5 (0.9)
Follow-up (months), median (range) 80 (12–158)
BCR
 No, n (%) 310 (56.8)
 Yes, n (%) 236 (43.2)
  PC NM
5mC (IHC), n (%)
 Total 344 328
 Score < 1 3 (0.8)
 Score = 1 160 (34.9) 126 (35.7)
 Score > 1 184 (40.2) 199 (56.4)
 Not determined 114 (24.9) 25 (7.1)
5hmC (IHC), n (%)
 Total 367 293
 Score < 1 27 (5.9) 8 (2.5)
 Score = 1 153 (33.4) 111 (34.0)
 Score > 1 187 (40.8) 174 (53.4)
 Not determined 91 (19.9) 33 (10.1)
5fC (IHC), n (%)
 Total 281 259
 Score < 1 155 (33.8) 163 (50.6)
 Score = 1 65 (14.2) 50 (15.5)
 Score > 1 61 (13.3) 46 (14.3)
 Not determined 177 (38.6) 63 (19.6)
5caC (IHC), n (%)
 Total 351 311
 Score < 1 102 (22.2) 146 (41.4)
 Score = 1 96 (21.0) 60 (17.0)
 Score > 1 153 (33.4) 105 (29.7)
 Not determined 107 (23.4) 42 (11.9)
ERG (IHC), n (%)
 Total 433 NA
ERG− 205 (44.8) NA
ERG+ 228 (49.8) NA
 Not determined 25 (5.4) NA
  1. Clinical data for the 546 RP patients analyzed on the TMA and distribution of IHC staining scores for each antibody in NM and PC tissue samples, respectively
  2. NA not applicable